-
April 23, 2024 Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility
-
April 22, 2024 Lupin Launches Mirabegron Extended-Release Tablets in the United States
-
April 12, 2024 U.S. FDA Completes Inspection of Lupin’s Dabhasa Facility with No Observations
-
April 9, 2024 Lupin Launches First Generic Version of Oracea® (Doxycycline Capsules) in the United States
-
April 8, 2024 Lupin Receives Approval from U.S. FDA for Valbenazine Capsules
-
April 3, 2024 Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer
-
April 1, 2024 Lupin Receives Tentative Approval from U.S. FDA for Migalastat Capsules
-
March 28, 2024 Lupin Receives Approval from U.S. FDA for Eslicarbazepine Acetate Tablets
-
March 19, 2024 Lupin Receives Approval from U.S. FDA for Aripiprazole Tablets, USP
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications